Company intelligence / Profile preview

Extraction Technologies Norway

Ski / Oslo area, Norwayetn-eme.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has developed and commercialized the ETN 12 EME instrument for rapid, efficient, and selective extraction of ionizable compounds from biological fluids such as blood and other body fluids. The EME platform has been validated in scientific publications for applications including drug analysis from hair samples and biological matrices[2]. First shipments to European customers occurred in August 2024; the product was highlighted at major industry events in 2024–2025[2].

Therapeutic areas: Other
Modalities: Sample preparation device/technology
Industry: Metabolite Diagnostics

Partnerships

Innovation Norway (early funding/support)Academic collaborations with University of Oslo Department of Pharmacy

Beyond the preview

Go deeper on Extraction Technologies Norway.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Extraction Technologies Norway.

Explore the full profile